APO Research
Talk to an analyst

APO RESEARCH · REPORT

Sexually Transmitted Diseases (STDs) Drug

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Sexually Transmitted Diseases (STDs) Drug Market Analysis and Forecast 2026-2032

26 December 2025194 pages

Choose your research edition.

Industry ResearchSexually Transmitted Diseases (STDs) Drug Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Sexually Transmitted Diseases (STDs) Drug Industry Growth and Trends Forecast to 2032109 pages · $3,450 USDMarket StructureGlobal Sexually Transmitted Diseases (STDs) Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Sexually Transmitted Diseases (STDs) Drug Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Sexually Transmitted Diseases (STDs) Drug Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Sexually Transmitted Diseases (STDs) Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Sexually Transmitted Diseases (STDs) Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Sexually Transmitted Diseases (STDs) Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Sexually Transmitted Diseases (STDs) Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Sexually Transmitted Diseases (STDs) Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Sexually Transmitted Diseases (STDs) Drug include Bayer Healthcare, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline Plc, Hoffmann La Roche, AbbVie, Inc., Pfizer, Eli Lilly and Merck & Co., Inc., etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Sexually Transmitted Diseases (STDs) Drug, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Sexually Transmitted Diseases (STDs) Drug, also provides the sales of main regions and countries. Of the upcoming market potential for Sexually Transmitted Diseases (STDs) Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Sexually Transmitted Diseases (STDs) Drug sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Sexually Transmitted Diseases (STDs) Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Sexually Transmitted Diseases (STDs) Drug sales, projected growth trends, production technology, application and end-user industry.

Sexually Transmitted Diseases (STDs) Drug Segment by Company

Bayer Healthcare

Bristol-Myers Squibb

Gilead Sciences

GlaxoSmithKline Plc

Hoffmann La Roche

AbbVie, Inc.

Pfizer

Eli Lilly

Merck & Co., Inc.

Johnson & Johnson

Sexually Transmitted Diseases (STDs) Drug Segment by Type

Chlamydia

Genital herpes

HPV

Syphilis

Gonorrhea

HIV / AIDS

Sexually Transmitted Diseases (STDs) Drug Segment by Application

Hospital Pharmacies

Online Pharmacies

Retail Pharmacies

Sexually Transmitted Diseases (STDs) Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Sexually Transmitted Diseases (STDs) Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Sexually Transmitted Diseases (STDs) Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Sexually Transmitted Diseases (STDs) Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Sexually Transmitted Diseases (STDs) Drug in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Sexually Transmitted Diseases (STDs) Drug manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Sexually Transmitted Diseases (STDs) Drug sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Sexually Transmitted Diseases (STDs) Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Chlamydia Major Manufacturers Table 3. Genital herpes Major Manufacturers Table 4. HPV Major Manufacturers Table 5. Syphilis Major Manufacturers Table 6. Gonorrhea Major Manufacturers Table 7. HIV / AIDS Major Manufacturers Table 8. Global Sexually Transmitted Diseases (STDs) Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 9. Hospital Pharmacies Major Manufacturers Table 10. Online Pharmacies Major Manufacturers Table 11. Retail Pharmacies Major Manufacturers Table 12. Sexually Transmitted Diseases (STDs) Drug Industry Trends Table 13. Sexually Transmitted Diseases (STDs) Drug Industry Drivers Table 14. Sexually Transmitted Diseases (STDs) Drug Industry Opportunities and Challenges Table 15. Sexually Transmitted Diseases (STDs) Drug Industry Restraints Table 16. Global Sexually Transmitted Diseases (STDs) Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Sexually Transmitted Diseases (STDs) Drug Revenue by Region (2021-2026) & (US$ Million) Table 18. Global Sexually Transmitted Diseases (STDs) Drug Revenue by Region (2027-2032) & (US$ Million) Table 19. Global Sexually Transmitted Diseases (STDs) Drug Revenue Market Share by Region (2021-2026) Table 20. Global Sexually Transmitted Diseases (STDs) Drug Revenue Market Share by Region (2027-2032) Table 21. Global Sexually Transmitted Diseases (STDs) Drug Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 22. Global Sexually Transmitted Diseases (STDs) Drug Sales by Region (2021-2026) & (K Units) Table 23. Global Sexually Transmitted Diseases (STDs) Drug Sales by Region (2027-2032) & (K Units) Table 24. Global Sexually Transmitted Diseases (STDs) Drug Sales Market Share by Region (2021-2026) Table 25. Global Sexually Transmitted Diseases (STDs) Drug Sales Market Share by Region (2027-2032) Table 26. Global Sexually Transmitted Diseases (STDs) Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 27. Global Sexually Transmitted Diseases (STDs) Drug Revenue Market Share by Manufacturers (2021-2026) Table 28. Global Sexually Transmitted Diseases (STDs) Drug Sales by Manufacturers (US$ Million) & (2021-2026) Table 29. Global Sexually Transmitted Diseases (STDs) Drug Sales Market Share by Manufacturers (2021-2026) Table 30. Global Sexually Transmitted Diseases (STDs) Drug Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 31. Global Sexually Transmitted Diseases (STDs) Drug Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 32. Global Sexually Transmitted Diseases (STDs) Drug Key Manufacturers Manufacturing Sites & Headquarters Table 33. Global Sexually Transmitted Diseases (STDs) Drug Manufacturers, Product Type & Application Table 34. Global Sexually Transmitted Diseases (STDs) Drug Manufacturers' Establishment Date Table 35. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 36. Global Sexually Transmitted Diseases (STDs) Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 37. Global Sexually Transmitted Diseases (STDs) Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Sexually Transmitted Diseases (STDs) Drug Revenue by Type (2021-2026) & (US$ Million) Table 39. Global Sexually Transmitted Diseases (STDs) Drug Revenue by Type (2027-2032) & (US$ Million) Table 40. Global Sexually Transmitted Diseases (STDs) Drug Revenue Market Share by Type (2021-2026) Table 41. Global Sexually Transmitted Diseases (STDs) Drug Revenue Market Share by Type (2027-2032) Table 42. Global Sexually Transmitted Diseases (STDs) Drug Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 43. Global Sexually Transmitted Diseases (STDs) Drug Sales by Type (2021-2026) & (K Units) Table 44. Global Sexually Transmitted Diseases (STDs) Drug Sales by Type (2027-2032) & (K Units) Table 45. Global Sexually Transmitted Diseases (STDs) Drug Sales Market Share by Type (2021-2026) Table 46. Global Sexually Transmitted Diseases (STDs) Drug Sales Market Share by Type (2027-2032) Table 47. Global Sexually Transmitted Diseases (STDs) Drug Price by Type (2021-2026) & (US$/Unit) Table 48. Global Sexually Transmitted Diseases (STDs) Drug Price by Type (2027-2032) & (US$/Unit) Table 49. Global Sexually Transmitted Diseases (STDs) Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Sexually Transmitted Diseases (STDs) Drug Revenue by Application (2021-2026) & (US$ Million) Table 51. Global Sexually Transmitted Diseases (STDs) Drug Revenue by Application (2027-2032) & (US$ Million) Table 52. Global Sexually Transmitted Diseases (STDs) Drug Revenue Market Share by Application (2021-2026) Table 53. Global Sexually Transmitted Diseases (STDs) Drug Revenue Market Share by Application (2027-2032) Table 54. Global Sexually Transmitted Diseases (STDs) Drug Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 55. Global Sexually Transmitted Diseases (STDs) Drug Sales by Application (2021-2026) & (K Units) Table 56. Global Sexually Transmitted Diseases (STDs) Drug Sales by Application (2027-2032) & (K Units) Table 57. Global Sexually Transmitted Diseases (STDs) Drug Sales Market Share by Application (2021-2026) Table 58. Global Sexually Transmitted Diseases (STDs) Drug Sales Market Share by Application (2027-2032) Table 59. Global Sexually Transmitted Diseases (STDs) Drug Price by Application (2021-2026) & (US$/Unit) Table 60. Global Sexually Transmitted Diseases (STDs) Drug Price by Application (2027-2032) & (US$/Unit) Table 61. Bayer Healthcare Company Information Table 62. Bayer Healthcare Business Overview Table 63. Bayer Healthcare Sexually Transmitted Diseases (STDs) Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 64. Bayer Healthcare Sexually Transmitted Diseases (STDs) Drug Product Portfolio Table 65. Bayer Healthcare Recent Development Table 66. Bristol-Myers Squibb Company Information Table 67. Bristol-Myers Squibb Business Overview Table 68. Bristol-Myers Squibb Sexually Transmitted Diseases (STDs) Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. Bristol-Myers Squibb Sexually Transmitted Diseases (STDs) Drug Product Portfolio Table 70. Bristol-Myers Squibb Recent Development Table 71. Gilead Sciences Company Information Table 72. Gilead Sciences Business Overview Table 73. Gilead Sciences Sexually Transmitted Diseases (STDs) Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Gilead Sciences Sexually Transmitted Diseases (STDs) Drug Product Portfolio Table 75. Gilead Sciences Recent Development Table 76. GlaxoSmithKline Plc Company Information Table 77. GlaxoSmithKline Plc Business Overview Table 78. GlaxoSmithKline Plc Sexually Transmitted Diseases (STDs) Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. GlaxoSmithKline Plc Sexually Transmitted Diseases (STDs) Drug Product Portfolio Table 80. GlaxoSmithKline Plc Recent Development Table 81. Hoffmann La Roche Company Information Table 82. Hoffmann La Roche Business Overview Table 83. Hoffmann La Roche Sexually Transmitted Diseases (STDs) Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Hoffmann La Roche Sexually Transmitted Diseases (STDs) Drug Product Portfolio Table 85. Hoffmann La Roche Recent Development Table 86. AbbVie, Inc. Company Information Table 87. AbbVie, Inc. Business Overview Table 88. AbbVie, Inc. Sexually Transmitted Diseases (STDs) Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. AbbVie, Inc. Sexually Transmitted Diseases (STDs) Drug Product Portfolio Table 90. AbbVie, Inc. Recent Development Table 91. Pfizer Company Information Table 92. Pfizer Business Overview Table 93. Pfizer Sexually Transmitted Diseases (STDs) Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Pfizer Sexually Transmitted Diseases (STDs) Drug Product Portfolio Table 95. Pfizer Recent Development Table 96. Eli Lilly Company Information Table 97. Eli Lilly Business Overview Table 98. Eli Lilly Sexually Transmitted Diseases (STDs) Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Eli Lilly Sexually Transmitted Diseases (STDs) Drug Product Portfolio Table 100. Eli Lilly Recent Development Table 101. Merck & Co., Inc. Company Information Table 102. Merck & Co., Inc. Business Overview Table 103. Merck & Co., Inc. Sexually Transmitted Diseases (STDs) Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Merck & Co., Inc. Sexually Transmitted Diseases (STDs) Drug Product Portfolio Table 105. Merck & Co., Inc. Recent Development Table 106. Johnson & Johnson Company Information Table 107. Johnson & Johnson Business Overview Table 108. Johnson & Johnson Sexually Transmitted Diseases (STDs) Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Johnson & Johnson Sexually Transmitted Diseases (STDs) Drug Product Portfolio Table 110. Johnson & Johnson Recent Development Table 111. North America Sexually Transmitted Diseases (STDs) Drug Revenue by Type (2021-2026) & (US$ Million) Table 112. North America Sexually Transmitted Diseases (STDs) Drug Revenue by Type (2027-2032) & (US$ Million) Table 113. North America Sexually Transmitted Diseases (STDs) Drug Sales by Type (2021-2026) & (K Units) Table 114. North America Sexually Transmitted Diseases (STDs) Drug Sales by Type (2027-2032) & (K Units) Table 115. North America Sexually Transmitted Diseases (STDs) Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 116. North America Sexually Transmitted Diseases (STDs) Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 117. North America Sexually Transmitted Diseases (STDs) Drug Revenue by Application (2021-2026) & (US$ Million) Table 118. North America Sexually Transmitted Diseases (STDs) Drug Revenue by Application (2027-2032) & (US$ Million) Table 119. North America Sexually Transmitted Diseases (STDs) Drug Sales by Application (2021-2026) & (K Units) Table 120. North America Sexually Transmitted Diseases (STDs) Drug Sales by Application (2027-2032) & (K Units) Table 121. North America Sexually Transmitted Diseases (STDs) Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 122. North America Sexually Transmitted Diseases (STDs) Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 123. North America Sexually Transmitted Diseases (STDs) Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 124. North America Sexually Transmitted Diseases (STDs) Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 125. North America Sexually Transmitted Diseases (STDs) Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 126. North America Sexually Transmitted Diseases (STDs) Drug Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 127. North America Sexually Transmitted Diseases (STDs) Drug Sales by Country (2021-2026) & (K Units) Table 128. North America Sexually Transmitted Diseases (STDs) Drug Sales by Country (2027-2032) & (K Units) Table 129. North America Sexually Transmitted Diseases (STDs) Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 130. North America Sexually Transmitted Diseases (STDs) Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 131. United States Sexually Transmitted Diseases (STDs) Drug Revenue (2021-2032) & (US$ Million) Table 132. Canada Sexually Transmitted Diseases (STDs) Drug Revenue (2021-2032) & (US$ Million) Table 133. Mexico Sexually Transmitted Diseases (STDs) Drug Revenue (2021-2032) & (US$ Million) Table 134. Europe Sexually Transmitted Diseases (STDs) Drug Revenue by Type (2021-2026) & (US$ Million) Table 135. Europe Sexually Transmitted Diseases (STDs) Drug Revenue by Type (2027-2032) & (US$ Million) Table 136. Europe Sexually Transmitted Diseases (STDs) Drug Sales by Type (2021-2026) & (K Units) Table 137. Europe Sexually Transmitted Diseases (STDs) Drug Sales by Type (2027-2032) & (K Units) Table 138. Europe Sexually Transmitted Diseases (STDs) Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 139. Europe Sexually Transmitted Diseases (STDs) Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 140. Europe Sexually Transmitted Diseases (STDs) Drug Revenue by Application (2021-2026) & (US$ Million) Table 141. Europe Sexually Transmitted Diseases (STDs) Drug Revenue by Application (2027-2032) & (US$ Million) Table 142. Europe Sexually Transmitted Diseases (STDs) Drug Sales by Application (2021-2026) & (K Units) Table 143. Europe Sexually Transmitted Diseases (STDs) Drug Sales by Application (2027-2032) & (K Units) Table 144. Europe Sexually Transmitted Diseases (STDs) Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 145. Europe Sexually Transmitted Diseases (STDs) Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 146. Europe Sexually Transmitted Diseases (STDs) Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 147. Europe Sexually Transmitted Diseases (STDs) Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 148. Europe Sexually Transmitted Diseases (STDs) Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 149. Europe Sexually Transmitted Diseases (STDs) Drug Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 150. Europe Sexually Transmitted Diseases (STDs) Drug Sales by Country (2021-2026) & (K Units) Table 151. Europe Sexually Transmitted Diseases (STDs) Drug Sales by Country (2027-2032) & (K Units) Table 152. Europe Sexually Transmitted Diseases (STDs) Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 153. Europe Sexually Transmitted Diseases (STDs) Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 154. Germany Sexually Transmitted Diseases (STDs) Drug Revenue (2021-2032) & (US$ Million) Table 155. France Sexually Transmitted Diseases (STDs) Drug Revenue (2021-2032) & (US$ Million) Table 156. U.K. Sexually Transmitted Diseases (STDs) Drug Revenue (2021-2032) & (US$ Million) Table 157. Italy Sexually Transmitted Diseases (STDs) Drug Revenue (2021-2032) & (US$ Million) Table 158. Russia Sexually Transmitted Diseases (STDs) Drug Revenue (2021-2032) & (US$ Million) Table 159. Spain Sexually Transmitted Diseases (STDs) Drug Revenue (2021-2032) & (US$ Million) Table 160. Netherlands Sexually Transmitted Diseases (STDs) Drug Revenue (2021-2032) & (US$ Million) Table 161. Switzerland Sexually Transmitted Diseases (STDs) Drug Revenue (2021-2032) & (US$ Million) Table 162. Sweden Sexually Transmitted Diseases (STDs) Drug Revenue (2021-2032) & (US$ Million) Table 163. Poland Sexually Transmitted Diseases (STDs) Drug Revenue (2021-2032) & (US$ Million) Table 164. China Sexually Transmitted Diseases (STDs) Drug Revenue by Type (2021-2026) & (US$ Million) Table 165. China Sexually Transmitted Diseases (STDs) Drug Revenue by Type (2027-2032) & (US$ Million) Table 166. China Sexually Transmitted Diseases (STDs) Drug Sales by Type (2021-2026) & (K Units) Table 167. China Sexually Transmitted Diseases (STDs) Drug Sales by Type (2027-2032) & (K Units) Table 168. China Sexually Transmitted Diseases (STDs) Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 169. China Sexually Transmitted Diseases (STDs) Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 170. China Sexually Transmitted Diseases (STDs) Drug Revenue by Application (2021-2026) & (US$ Million) Table 171. China Sexually Transmitted Diseases (STDs) Drug Revenue by Application (2027-2032) & (US$ Million) Table 172. China Sexually Transmitted Diseases (STDs) Drug Sales by Application (2021-2026) & (K Units) Table 173. China Sexually Transmitted Diseases (STDs) Drug Sales by Application (2027-2032) & (K Units) Table 174. China Sexually Transmitted Diseases (STDs) Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 175. China Sexually Transmitted Diseases (STDs) Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 176. Asia Sexually Transmitted Diseases (STDs) Drug Revenue by Type (2021-2026) & (US$ Million) Table 177. Asia Sexually Transmitted Diseases (STDs) Drug Revenue by Type (2027-2032) & (US$ Million) Table 178. Asia Sexually Transmitted Diseases (STDs) Drug Sales by Type (2021-2026) & (K Units) Table 179. Asia Sexually Transmitted Diseases (STDs) Drug Sales by Type (2027-2032) & (K Units) Table 180. Asia Sexually Transmitted Diseases (STDs) Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 181. Asia Sexually Transmitted Diseases (STDs) Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 182. Asia Sexually Transmitted Diseases (STDs) Drug Revenue by Application (2021-2026) & (US$ Million) Table 183. Asia Sexually Transmitted Diseases (STDs) Drug Revenue by Application (2027-2032) & (US$ Million) Table 184. Asia Sexually Transmitted Diseases (STDs) Drug Sales by Application (2021-2026) & (K Units) Table 185. Asia Sexually Transmitted Diseases (STDs) Drug Sales by Application (2027-2032) & (K Units) Table 186. Asia Sexually Transmitted Diseases (STDs) Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 187. Asia Sexually Transmitted Diseases (STDs) Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 188. Asia Sexually Transmitted Diseases (STDs) Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 189. Asia Sexually Transmitted Diseases (STDs) Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 190. Asia Sexually Transmitted Diseases (STDs) Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 191. Asia Sexually Transmitted Diseases (STDs) Drug Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 192. Asia Sexually Transmitted Diseases (STDs) Drug Sales by Country (2021-2026) & (K Units) Table 193. Asia Sexually Transmitted Diseases (STDs) Drug Sales by Country (2027-2032) & (K Units) Table 194. Asia Sexually Transmitted Diseases (STDs) Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 195. Asia Sexually Transmitted Diseases (STDs) Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 196. Japan Sexually Transmitted Diseases (STDs) Drug Revenue (2021-2032) & (US$ Million) Table 197. South Korea Sexually Transmitted Diseases (STDs) Drug Revenue (2021-2032) & (US$ Million) Table 198. India Sexually Transmitted Diseases (STDs) Drug Revenue (2021-2032) & (US$ Million) Table 199. Australia Sexually Transmitted Diseases (STDs) Drug Revenue (2021-2032) & (US$ Million) Table 200. Taiwan Sexually Transmitted Diseases (STDs) Drug Revenue (2021-2032) & (US$ Million) Table 201. Southeast Asia Sexually Transmitted Diseases (STDs) Drug Revenue (2021-2032) & (US$ Million) Table 202. SAMEA Sexually Transmitted Diseases (STDs) Drug Revenue by Type (2021-2026) & (US$ Million) Table 203. SAMEA Sexually Transmitted Diseases (STDs) Drug Revenue by Type (2027-2032) & (US$ Million) Table 204. SAMEA Sexually Transmitted Diseases (STDs) Drug Sales by Type (2021-2026) & (K Units) Table 205. SAMEA Sexually Transmitted Diseases (STDs) Drug Sales by Type (2027-2032) & (K Units) Table 206. SAMEA Sexually Transmitted Diseases (STDs) Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 207. SAMEA Sexually Transmitted Diseases (STDs) Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 208. SAMEA Sexually Transmitted Diseases (STDs) Drug Revenue by Application (2021-2026) & (US$ Million) Table 209. SAMEA Sexually Transmitted Diseases (STDs) Drug Revenue by Application (2027-2032) & (US$ Million) Table 210. SAMEA Sexually Transmitted Diseases (STDs) Drug Sales by Application (2021-2026) & (K Units) Table 211. SAMEA Sexually Transmitted Diseases (STDs) Drug Sales by Application (2027-2032) & (K Units) Table 212. SAMEA Sexually Transmitted Diseases (STDs) Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 213. SAMEA Sexually Transmitted Diseases (STDs) Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 214. SAMEA Sexually Transmitted Diseases (STDs) Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 215. SAMEA Sexually Transmitted Diseases (STDs) Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 216. SAMEA Sexually Transmitted Diseases (STDs) Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 217. SAMEA Sexually Transmitted Diseases (STDs) Drug Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 218. SAMEA Sexually Transmitted Diseases (STDs) Drug Sales by Country (2021-2026) & (K Units) Table 219. SAMEA Sexually Transmitted Diseases (STDs) Drug Sales by Country (2027-2032) & (K Units) Table 220. SAMEA Sexually Transmitted Diseases (STDs) Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 221. SAMEA Sexually Transmitted Diseases (STDs) Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 222. Brazil Sexually Transmitted Diseases (STDs) Drug Revenue (2021-2032) & (US$ Million) Table 223. Argentina Sexually Transmitted Diseases (STDs) Drug Revenue (2021-2032) & (US$ Million) Table 224. Chile Sexually Transmitted Diseases (STDs) Drug Revenue (2021-2032) & (US$ Million) Table 225. Colombia Sexually Transmitted Diseases (STDs) Drug Revenue (2021-2032) & (US$ Million) Table 226. Peru Sexually Transmitted Diseases (STDs) Drug Revenue (2021-2032) & (US$ Million) Table 227. Saudi Arabia Sexually Transmitted Diseases (STDs) Drug Revenue (2021-2032) & (US$ Million) Table 228. Israel Sexually Transmitted Diseases (STDs) Drug Revenue (2021-2032) & (US$ Million) Table 229. UAE Sexually Transmitted Diseases (STDs) Drug Revenue (2021-2032) & (US$ Million) Table 230. Turkey Sexually Transmitted Diseases (STDs) Drug Revenue (2021-2032) & (US$ Million) Table 231. Iran Sexually Transmitted Diseases (STDs) Drug Revenue (2021-2032) & (US$ Million) Table 232. Egypt Sexually Transmitted Diseases (STDs) Drug Revenue (2021-2032) & (US$ Million) Table 233. Key Raw Materials Table 234. Raw Materials Key Suppliers Table 235. Sexually Transmitted Diseases (STDs) Drug Distributors List Table 236. Sexually Transmitted Diseases (STDs) Drug Customers List Table 237. Research Programs/Design for This Report Table 238. Authors List of This Report Table 239. Secondary Sources Table 240. Primary Sources List of Figures Figure 1. Sexually Transmitted Diseases (STDs) Drug Image Figure 2. Global Sexually Transmitted Diseases (STDs) Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Sexually Transmitted Diseases (STDs) Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. Chlamydia Image Figure 5. Genital herpes Image Figure 6. HPV Image Figure 7. Syphilis Image Figure 8. Gonorrhea Image Figure 9. HIV / AIDS Image Figure 10. Global Sexually Transmitted Diseases (STDs) Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 11. Global Sexually Transmitted Diseases (STDs) Drug Market Size Share 2021 VS 2025 VS 2032 Figure 12. Hospital Pharmacies Image Figure 13. Online Pharmacies Image Figure 14. Retail Pharmacies Image Figure 15. Global Sexually Transmitted Diseases (STDs) Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Sexually Transmitted Diseases (STDs) Drug Revenue (2021-2032) & (US$ Million) Figure 17. Global Sexually Transmitted Diseases (STDs) Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 18. Global Sexually Transmitted Diseases (STDs) Drug Revenue Market Share by Region: 2025 Versus 2032 Figure 19. Global Sexually Transmitted Diseases (STDs) Drug Revenue Market Share by Region (2021-2032) Figure 20. Global Sexually Transmitted Diseases (STDs) Drug Sales (2021-2032) & (K Units) Figure 21. Global Sexually Transmitted Diseases (STDs) Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 22. Global Sexually Transmitted Diseases (STDs) Drug Sales Market Share by Region (2021-2032) Figure 23. US & Canada & Mexico Sexually Transmitted Diseases (STDs) Drug Sales YoY (2021-2032) & (K Units) Figure 24. Europe Sexually Transmitted Diseases (STDs) Drug Sales YoY (2021-2032) & (K Units) Figure 25. China Sexually Transmitted Diseases (STDs) Drug Sales YoY (2021-2032) & (K Units) Figure 26. Asia (Excluding China) Sexually Transmitted Diseases (STDs) Drug Sales YoY (2021-2032) & (K Units) Figure 27. South America, Middle East and Africa Sexually Transmitted Diseases (STDs) Drug Sales YoY (2021-2032) & (K Units) Figure 28. Global Sexually Transmitted Diseases (STDs) Drug Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 29. Global Sexually Transmitted Diseases (STDs) Drug Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 30. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 31. Global Sexually Transmitted Diseases (STDs) Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 32. Global Sexually Transmitted Diseases (STDs) Drug Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 33. Global Sexually Transmitted Diseases (STDs) Drug Revenue Market Share by Type (2021-2032) Figure 34. Global Sexually Transmitted Diseases (STDs) Drug Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 35. Global Sexually Transmitted Diseases (STDs) Drug Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 36. Global Sexually Transmitted Diseases (STDs) Drug Sales Market Share by Type (2021-2032) Figure 37. Global Sexually Transmitted Diseases (STDs) Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 38. Global Sexually Transmitted Diseases (STDs) Drug Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 39. Global Sexually Transmitted Diseases (STDs) Drug Revenue Market Share by Application (2021-2032) Figure 40. Global Sexually Transmitted Diseases (STDs) Drug Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 41. Global Sexually Transmitted Diseases (STDs) Drug Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 42. Global Sexually Transmitted Diseases (STDs) Drug Sales Market Share by Application (2021-2032) Figure 43. North America Sexually Transmitted Diseases (STDs) Drug Revenue Share by Type (2021-2032) Figure 44. North America Sexually Transmitted Diseases (STDs) Drug Sales Share by Type (2021-2032) Figure 45. North America Sexually Transmitted Diseases (STDs) Drug Revenue Share by Application (2021-2032) Figure 46. North America Sexually Transmitted Diseases (STDs) Drug Sales Share by Application (2021-2032) Figure 47. North America Sexually Transmitted Diseases (STDs) Drug Revenue Share by Country (2021-2032) Figure 48. North America Sexually Transmitted Diseases (STDs) Drug Sales Share by Country (2021-2032) Figure 49. Europe Sexually Transmitted Diseases (STDs) Drug Revenue Share by Type (2021-2032) Figure 50. Europe Sexually Transmitted Diseases (STDs) Drug Sales Share by Type (2021-2032) Figure 51. Europe Sexually Transmitted Diseases (STDs) Drug Revenue Share by Application (2021-2032) Figure 52. Europe Sexually Transmitted Diseases (STDs) Drug Sales Share by Application (2021-2032) Figure 53. Europe Sexually Transmitted Diseases (STDs) Drug Revenue Share by Country (2021-2032) Figure 54. Europe Sexually Transmitted Diseases (STDs) Drug Sales Share by Country (2021-2032) Figure 55. China Sexually Transmitted Diseases (STDs) Drug Revenue Share by Type (2021-2032) Figure 56. China Sexually Transmitted Diseases (STDs) Drug Sales Share by Type (2021-2032) Figure 57. China Sexually Transmitted Diseases (STDs) Drug Revenue Share by Application (2021-2032) Figure 58. China Sexually Transmitted Diseases (STDs) Drug Sales Share by Application (2021-2032) Figure 59. Asia Sexually Transmitted Diseases (STDs) Drug Revenue Share by Type (2021-2032) Figure 60. Asia Sexually Transmitted Diseases (STDs) Drug Sales Share by Type (2021-2032) Figure 61. Asia Sexually Transmitted Diseases (STDs) Drug Revenue Share by Application (2021-2032) Figure 62. Asia Sexually Transmitted Diseases (STDs) Drug Sales Share by Application (2021-2032) Figure 63. Asia Sexually Transmitted Diseases (STDs) Drug Revenue Share by Country (2021-2032) Figure 64. Asia Sexually Transmitted Diseases (STDs) Drug Sales Share by Country (2021-2032) Figure 65. SAMEA Sexually Transmitted Diseases (STDs) Drug Revenue Share by Type (2021-2032) Figure 66. SAMEA Sexually Transmitted Diseases (STDs) Drug Sales Share by Type (2021-2032) Figure 67. SAMEA Sexually Transmitted Diseases (STDs) Drug Revenue Share by Application (2021-2032) Figure 68. SAMEA Sexually Transmitted Diseases (STDs) Drug Sales Share by Application (2021-2032) Figure 69. SAMEA Sexually Transmitted Diseases (STDs) Drug Revenue Share by Country (2021-2032) Figure 70. SAMEA Sexually Transmitted Diseases (STDs) Drug Sales Share by Country (2021-2032) Figure 71. Sexually Transmitted Diseases (STDs) Drug Value Chain Figure 72. Manufacturing Cost Structure Figure 73. Sexually Transmitted Diseases (STDs) Drug Production Mode & Process Figure 74. Direct Comparison with Distribution Share Figure 75. Distributors Profiles Figure 76. Years Considered Figure 77. Research Process Figure 78. Key Executives Interviewed

Scope & coverage.

Types
  • Chlamydia
  • Genital herpes
  • HPV
  • Syphilis
  • Gonorrhea
  • HIV / AIDS
Applications
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
Companies covered
  • Bayer Healthcare
  • Bristol-Myers Squibb
  • Gilead Sciences
  • GlaxoSmithKline Plc
  • Hoffmann La Roche
  • AbbVie, Inc.
  • Pfizer
  • Eli Lilly
  • Merck & Co., Inc.
  • Johnson & Johnson

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Sexually Transmitted Diseases (STDs) Drug Market by Type
  3. 1.2.1 Global Sexually Transmitted Diseases (STDs) Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Chlamydia
  5. 1.2.3 Genital herpes
  6. 1.2.4 HPV
  7. 1.2.5 Syphilis
  8. 1.2.6 Gonorrhea
  9. 1.2.7 HIV / AIDS
  10. 1.3 Sexually Transmitted Diseases (STDs) Drug Market by Application
  11. 1.3.1 Global Sexually Transmitted Diseases (STDs) Drug Market Size by Application, 2021 VS 2025 VS 2032
  12. 1.3.2 Hospital Pharmacies
  13. 1.3.3 Online Pharmacies
  14. 1.3.4 Retail Pharmacies
  15. 1.4 Assumptions and Limitations
  16. 1.5 Study Goals and Objectives
2 Sexually Transmitted Diseases (STDs) Drug Market Dynamics
  1. 2.1 Sexually Transmitted Diseases (STDs) Drug Industry Trends
  2. 2.2 Sexually Transmitted Diseases (STDs) Drug Industry Drivers
  3. 2.3 Sexually Transmitted Diseases (STDs) Drug Industry Opportunities and Challenges
  4. 2.4 Sexually Transmitted Diseases (STDs) Drug Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Sexually Transmitted Diseases (STDs) Drug Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Sexually Transmitted Diseases (STDs) Drug Revenue by Region
  3. 3.2.1 Global Sexually Transmitted Diseases (STDs) Drug Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Sexually Transmitted Diseases (STDs) Drug Revenue by Region (2021-2026)
  5. 3.2.3 Global Sexually Transmitted Diseases (STDs) Drug Revenue by Region (2027-2032)
  6. 3.2.4 Global Sexually Transmitted Diseases (STDs) Drug Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Sexually Transmitted Diseases (STDs) Drug Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Sexually Transmitted Diseases (STDs) Drug Sales by Region
  9. 3.4.1 Global Sexually Transmitted Diseases (STDs) Drug Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Sexually Transmitted Diseases (STDs) Drug Sales by Region (2021-2026)
  11. 3.4.3 Global Sexually Transmitted Diseases (STDs) Drug Sales by Region (2027-2032)
  12. 3.4.4 Global Sexually Transmitted Diseases (STDs) Drug Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Sexually Transmitted Diseases (STDs) Drug Revenue by Manufacturers
  2. 4.1.1 Global Sexually Transmitted Diseases (STDs) Drug Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Sexually Transmitted Diseases (STDs) Drug Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Sexually Transmitted Diseases (STDs) Drug Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Sexually Transmitted Diseases (STDs) Drug Sales by Manufacturers
  6. 4.2.1 Global Sexually Transmitted Diseases (STDs) Drug Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Sexually Transmitted Diseases (STDs) Drug Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Sexually Transmitted Diseases (STDs) Drug Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Sexually Transmitted Diseases (STDs) Drug Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Sexually Transmitted Diseases (STDs) Drug Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Sexually Transmitted Diseases (STDs) Drug Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Sexually Transmitted Diseases (STDs) Drug Manufacturers, Product Type & Application
  13. 4.7 Global Sexually Transmitted Diseases (STDs) Drug Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Sexually Transmitted Diseases (STDs) Drug Market CR5 and HHI
  16. 4.8.2 2025 Sexually Transmitted Diseases (STDs) Drug Tier 1, Tier 2, and Tier 3
5 Sexually Transmitted Diseases (STDs) Drug Market by Type
  1. 5.1 Global Sexually Transmitted Diseases (STDs) Drug Revenue by Type
  2. 5.1.1 Global Sexually Transmitted Diseases (STDs) Drug Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Sexually Transmitted Diseases (STDs) Drug Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Sexually Transmitted Diseases (STDs) Drug Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Sexually Transmitted Diseases (STDs) Drug Sales by Type
  6. 5.2.1 Global Sexually Transmitted Diseases (STDs) Drug Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Sexually Transmitted Diseases (STDs) Drug Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Sexually Transmitted Diseases (STDs) Drug Sales Market Share by Type (2021-2032)
  9. 5.3 Global Sexually Transmitted Diseases (STDs) Drug Price by Type
6 Sexually Transmitted Diseases (STDs) Drug Market by Application
  1. 6.1 Global Sexually Transmitted Diseases (STDs) Drug Revenue by Application
  2. 6.1.1 Global Sexually Transmitted Diseases (STDs) Drug Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Sexually Transmitted Diseases (STDs) Drug Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Sexually Transmitted Diseases (STDs) Drug Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Sexually Transmitted Diseases (STDs) Drug Sales by Application
  6. 6.2.1 Global Sexually Transmitted Diseases (STDs) Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Sexually Transmitted Diseases (STDs) Drug Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Sexually Transmitted Diseases (STDs) Drug Sales Market Share by Application (2021-2032)
  9. 6.3 Global Sexually Transmitted Diseases (STDs) Drug Price by Application
7 Company Profiles
  1. 7.1 Bayer Healthcare
  2. 7.1.1 Bayer Healthcare Company Information
  3. 7.1.2 Bayer Healthcare Business Overview
  4. 7.1.3 Bayer Healthcare Sexually Transmitted Diseases (STDs) Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Bayer Healthcare Sexually Transmitted Diseases (STDs) Drug Product Portfolio
  6. 7.1.5 Bayer Healthcare Recent Developments
  7. 7.2 Bristol-Myers Squibb
  8. 7.2.1 Bristol-Myers Squibb Company Information
  9. 7.2.2 Bristol-Myers Squibb Business Overview
  10. 7.2.3 Bristol-Myers Squibb Sexually Transmitted Diseases (STDs) Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Bristol-Myers Squibb Sexually Transmitted Diseases (STDs) Drug Product Portfolio
  12. 7.2.5 Bristol-Myers Squibb Recent Developments
  13. 7.3 Gilead Sciences
  14. 7.3.1 Gilead Sciences Company Information
  15. 7.3.2 Gilead Sciences Business Overview
  16. 7.3.3 Gilead Sciences Sexually Transmitted Diseases (STDs) Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Gilead Sciences Sexually Transmitted Diseases (STDs) Drug Product Portfolio
  18. 7.3.5 Gilead Sciences Recent Developments
  19. 7.4 GlaxoSmithKline Plc
  20. 7.4.1 GlaxoSmithKline Plc Company Information
  21. 7.4.2 GlaxoSmithKline Plc Business Overview
  22. 7.4.3 GlaxoSmithKline Plc Sexually Transmitted Diseases (STDs) Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 GlaxoSmithKline Plc Sexually Transmitted Diseases (STDs) Drug Product Portfolio
  24. 7.4.5 GlaxoSmithKline Plc Recent Developments
  25. 7.5 Hoffmann La Roche
  26. 7.5.1 Hoffmann La Roche Company Information
  27. 7.5.2 Hoffmann La Roche Business Overview
  28. 7.5.3 Hoffmann La Roche Sexually Transmitted Diseases (STDs) Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Hoffmann La Roche Sexually Transmitted Diseases (STDs) Drug Product Portfolio
  30. 7.5.5 Hoffmann La Roche Recent Developments
  31. 7.6 AbbVie, Inc.
  32. 7.6.1 AbbVie, Inc. Company Information
  33. 7.6.2 AbbVie, Inc. Business Overview
  34. 7.6.3 AbbVie, Inc. Sexually Transmitted Diseases (STDs) Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 AbbVie, Inc. Sexually Transmitted Diseases (STDs) Drug Product Portfolio
  36. 7.6.5 AbbVie, Inc. Recent Developments
  37. 7.7 Pfizer
  38. 7.7.1 Pfizer Company Information
  39. 7.7.2 Pfizer Business Overview
  40. 7.7.3 Pfizer Sexually Transmitted Diseases (STDs) Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Pfizer Sexually Transmitted Diseases (STDs) Drug Product Portfolio
  42. 7.7.5 Pfizer Recent Developments
  43. 7.8 Eli Lilly
  44. 7.8.1 Eli Lilly Company Information
  45. 7.8.2 Eli Lilly Business Overview
  46. 7.8.3 Eli Lilly Sexually Transmitted Diseases (STDs) Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Eli Lilly Sexually Transmitted Diseases (STDs) Drug Product Portfolio
  48. 7.8.5 Eli Lilly Recent Developments
  49. 7.9 Merck & Co., Inc.
  50. 7.9.1 Merck & Co., Inc. Company Information
  51. 7.9.2 Merck & Co., Inc. Business Overview
  52. 7.9.3 Merck & Co., Inc. Sexually Transmitted Diseases (STDs) Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Merck & Co., Inc. Sexually Transmitted Diseases (STDs) Drug Product Portfolio
  54. 7.9.5 Merck & Co., Inc. Recent Developments
  55. 7.10 Johnson & Johnson
  56. 7.10.1 Johnson & Johnson Company Information
  57. 7.10.2 Johnson & Johnson Business Overview
  58. 7.10.3 Johnson & Johnson Sexually Transmitted Diseases (STDs) Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Johnson & Johnson Sexually Transmitted Diseases (STDs) Drug Product Portfolio
  60. 7.10.5 Johnson & Johnson Recent Developments
8 North America
  1. 8.1 North America Sexually Transmitted Diseases (STDs) Drug Market Size by Type
  2. 8.1.1 North America Sexually Transmitted Diseases (STDs) Drug Revenue by Type (2021-2032)
  3. 8.1.2 North America Sexually Transmitted Diseases (STDs) Drug Sales by Type (2021-2032)
  4. 8.1.3 North America Sexually Transmitted Diseases (STDs) Drug Price by Type (2021-2032)
  5. 8.2 North America Sexually Transmitted Diseases (STDs) Drug Market Size by Application
  6. 8.2.1 North America Sexually Transmitted Diseases (STDs) Drug Revenue by Application (2021-2032)
  7. 8.2.2 North America Sexually Transmitted Diseases (STDs) Drug Sales by Application (2021-2032)
  8. 8.2.3 North America Sexually Transmitted Diseases (STDs) Drug Price by Application (2021-2032)
  9. 8.3 North America Sexually Transmitted Diseases (STDs) Drug Market Size by Country
  10. 8.3.1 North America Sexually Transmitted Diseases (STDs) Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Sexually Transmitted Diseases (STDs) Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Sexually Transmitted Diseases (STDs) Drug Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Sexually Transmitted Diseases (STDs) Drug Market Size by Type
  2. 9.1.1 Europe Sexually Transmitted Diseases (STDs) Drug Revenue by Type (2021-2032)
  3. 9.1.2 Europe Sexually Transmitted Diseases (STDs) Drug Sales by Type (2021-2032)
  4. 9.1.3 Europe Sexually Transmitted Diseases (STDs) Drug Price by Type (2021-2032)
  5. 9.2 Europe Sexually Transmitted Diseases (STDs) Drug Market Size by Application
  6. 9.2.1 Europe Sexually Transmitted Diseases (STDs) Drug Revenue by Application (2021-2032)
  7. 9.2.2 Europe Sexually Transmitted Diseases (STDs) Drug Sales by Application (2021-2032)
  8. 9.2.3 Europe Sexually Transmitted Diseases (STDs) Drug Price by Application (2021-2032)
  9. 9.3 Europe Sexually Transmitted Diseases (STDs) Drug Market Size by Country
  10. 9.3.1 Europe Sexually Transmitted Diseases (STDs) Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Sexually Transmitted Diseases (STDs) Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Sexually Transmitted Diseases (STDs) Drug Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Sexually Transmitted Diseases (STDs) Drug Market Size by Type
  2. 10.1.1 China Sexually Transmitted Diseases (STDs) Drug Revenue by Type (2021-2032)
  3. 10.1.2 China Sexually Transmitted Diseases (STDs) Drug Sales by Type (2021-2032)
  4. 10.1.3 China Sexually Transmitted Diseases (STDs) Drug Price by Type (2021-2032)
  5. 10.2 China Sexually Transmitted Diseases (STDs) Drug Market Size by Application
  6. 10.2.1 China Sexually Transmitted Diseases (STDs) Drug Revenue by Application (2021-2032)
  7. 10.2.2 China Sexually Transmitted Diseases (STDs) Drug Sales by Application (2021-2032)
  8. 10.2.3 China Sexually Transmitted Diseases (STDs) Drug Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Sexually Transmitted Diseases (STDs) Drug Market Size by Type
  2. 11.1.1 Asia Sexually Transmitted Diseases (STDs) Drug Revenue by Type (2021-2032)
  3. 11.1.2 Asia Sexually Transmitted Diseases (STDs) Drug Sales by Type (2021-2032)
  4. 11.1.3 Asia Sexually Transmitted Diseases (STDs) Drug Price by Type (2021-2032)
  5. 11.2 Asia Sexually Transmitted Diseases (STDs) Drug Market Size by Application
  6. 11.2.1 Asia Sexually Transmitted Diseases (STDs) Drug Revenue by Application (2021-2032)
  7. 11.2.2 Asia Sexually Transmitted Diseases (STDs) Drug Sales by Application (2021-2032)
  8. 11.2.3 Asia Sexually Transmitted Diseases (STDs) Drug Price by Application (2021-2032)
  9. 11.3 Asia Sexually Transmitted Diseases (STDs) Drug Market Size by Country
  10. 11.3.1 Asia Sexually Transmitted Diseases (STDs) Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Sexually Transmitted Diseases (STDs) Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Sexually Transmitted Diseases (STDs) Drug Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Sexually Transmitted Diseases (STDs) Drug Market Size by Type
  2. 12.1.1 SAMEA Sexually Transmitted Diseases (STDs) Drug Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Sexually Transmitted Diseases (STDs) Drug Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Sexually Transmitted Diseases (STDs) Drug Price by Type (2021-2032)
  5. 12.2 SAMEA Sexually Transmitted Diseases (STDs) Drug Market Size by Application
  6. 12.2.1 SAMEA Sexually Transmitted Diseases (STDs) Drug Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Sexually Transmitted Diseases (STDs) Drug Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Sexually Transmitted Diseases (STDs) Drug Price by Application (2021-2032)
  9. 12.3 SAMEA Sexually Transmitted Diseases (STDs) Drug Market Size by Country
  10. 12.3.1 SAMEA Sexually Transmitted Diseases (STDs) Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Sexually Transmitted Diseases (STDs) Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Sexually Transmitted Diseases (STDs) Drug Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Sexually Transmitted Diseases (STDs) Drug Value Chain Analysis
  2. 13.1.1 Sexually Transmitted Diseases (STDs) Drug Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Sexually Transmitted Diseases (STDs) Drug Production Mode & Process
  6. 13.2 Sexually Transmitted Diseases (STDs) Drug Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Sexually Transmitted Diseases (STDs) Drug Distributors
  9. 13.2.3 Sexually Transmitted Diseases (STDs) Drug Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst